Psilocybin in the treatment of obsessive-compulsive disorder: What do we know so far?. (13th April 2021)

• Record Type: Journal Article
• Authors: Descalço, N.; Medeiros, A.B.; Santos, C. Fernandes; Borges, G.
• Is Part Of: European psychiatry. Volume 64:Supplement 1(2021)
• Page Start: S417
• Page End: S417
• Publication Date: 2021-04-13
• Subjects: Obsessive-Compulsive disorder -- Psilocybin -- Hallucinogens; Psychiatry -- Periodicals; Mental illness -- Periodicals; Electronic journals; 616.89
• DOI: 10.1192/j.eurpsy.2021.1114
• Languages: English
• ISSNs: 0924-9338

Abstract

Abstract : Introduction: Psilocybin is a naturally occurring plant alkaloid in mushrooms and a prodrug of psilocin. It is a serotonin receptor (5-HT2A) agonist and known psychedelic, with similar hallucinatory properties to lysergic acid diethylamide (LSD). It has been identified as a safe and effective option in treatment-resistant depression. Literature focus mainly on its use on depressive but its interest in other psychiatric disorders such as obsessive-compulsive disorder (OCD) has grown. Objectives: To review the clinical evidence for the use of hallucinogens such as psilocybin in OCD. Methods: Non-systematic review of literature found on PubMed/MEDLINE, Web of Science and Google Scholar, using the keywords "obsessive-compulsive disorder", "psilocybin" and "hallucinogens". Articles may include clinical trials, case report or case series. Articles found were admitted according to their relevance for the topic in review; only articles in English were included. Ongoing research trials on this topic were checked on ClinicalTrials.gov. Results: So far, only one open-label non-randomized study directly assessed the effects of psilocybin on OCD patients that found acute reductions of obsessive-compulsive symptoms. Case reports of patients improving with off-label use of psilocybin are reported. There are two ongoing phase I research trials, aiming to explore the effect of the substance on symptomatology, hypothesizing that psilocybin will normalize cerebral connectivity and thus correlate with clinical improvement. Conclusions: More research to establish the usefulness of psilocybin in OCD patients is needed; the collected data is encouraging are there may be a role for its use on this disorder.